Tianjin Medical Journal

Tianjin Medical Journal ›› 2021, Vol. 49 ›› Issue (10): 1116-1120.doi: 10.11958/20210786

Previous Articles    

Research progress of SGLT2 inhibitor in the occurrence of atrial fibrillation

SHAO Qing-miao, ZHANG Tao, LIU Tong, LI Guang-ping #br#   

  1. 1 Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of
    Cardiology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China; 2 Department of Nephrology, the First
    Teaching Hospital of Tianjin University of Traditional Chinese Medicine
  • Received:2021-04-02 Revised:2021-05-10 Published:2021-10-15 Online:2021-10-15
  • Contact: Qing-Miao SHAO E-mail:shaoqingmiao@126.com

PDF (PC)

2854

Abstract: Diabetes and its complications are closely related to the high incidence rate of atrial fibrillation (AF). Sodium-glucose cotransporter-2 inhibitor (SGLT2i), as a new type of hypoglycemic drugs, can reduce the renal glucose threshold by inhibiting SGLT2 receptor and ultimately achieve the hypoglycemic effect by promoting urine glucose excretion. In addition to the hypoglycemic effect, SGLT2i also has a series of beneficial effects such as reducing blood pressure, reducing body weight, lowering blood uric acid and reducing proteinuria. SGLT2i can not only reduce the risk of cardiovascular death and heart failure, but also more and more evidence shows that SGLT2i plays an important role in reducing AF occurrence. This paper summarizes the potential role of SGLT2i in AF, and its related mechanisms, which provides a new way for the prevention and treatment of AF.

Key words: diabetes mellitus, type 2, atrial fibrillation, sodium-glucose transporter 2, mitochondria, sodium-glucose
cotransporter-2 inhibitors